8:03 AM
 | 
Oct 12, 2018
 |  BioCentury  |  Finance

A Glympse at drug response

How Glympse’s diagnostics business model attracted a $22M A round

Investors poured $22 million into Glympse Bio Inc.’s series A round after the company established plans to apply its sensors to both diagnostics and drug response monitoring.

Polaris Partners and Arch Venture Partners co-led the untranched round, which closed on Oct. 9. Fellow new investors Charles River Ventures, Gilead Sciences Inc. (NASDAQ:GILD), Yonghua Capital and Inevitable Ventures and existing investors GreatPoint Ventures, Heritage Provider Network and Rivas Capital also participated.

The company is developing non-invasive bio-engineered activity sensors that emit a signal detectable in urine.

“It developed a commercially viable therapeutic and...

Read the full 447 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >